Organon & Co. (OGN)
(Delayed Data from NYSE)
$19.05 USD
+0.40 (2.14%)
Updated Aug 7, 2024 04:00 PM ET
After-Market: $19.05 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth A Momentum A VGM
Organon (OGN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$21.29 | $27.00 | $16.00 | 14.16% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Organon comes to $21.29. The forecasts range from a low of $16.00 to a high of $27.00. The average price target represents an increase of 14.16% from the last closing price of $18.65.
Analyst Price Targets (7 )
Broker Rating
Organon currently has an average brokerage recommendation (ABR) of 2.57 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 2.57 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, two are Strong Buy, representing 28.57% of all recommendations. A month ago, Strong Buy represented 28.57%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/OGN.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 4 | 4 | 4 | 4 | 4 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.57 | 2.57 | 2.57 | 2.57 | 2.57 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/3/2024 | Goldman Sachs | Chris Shibutani | Hold | Hold |
4/29/2024 | Piper Sandler | David Amsellem | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Steve M Scala | Hold | Hold |
2/14/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.57 |
ABR (Last week) | 2.57 |
# of Recs in ABR | 7 |
Average Target Price | $21.29 |
LT Growth Rate | 5.10% |
Industry | Medical Services |
Industry Rank by ABR | 151 of 253 |
Current Quarter EPS Est: | 1.08 |